A lot of moving parts in this agreement. BRL thinks Seasonique is a big deal and Shire is gaining the rights to it in the major countries of Western Europe. I can imagine a large demand from women in those countries to have only four periods per year.
Why does BRL need to purchase ordinary (non-extended-release) Adderall from Shire when BRL is already selling such a product? That’s the one part of the agreement I don’t understand.
BRL is the best in the business at crafting these kinds of settlements.
Market Data 
Markets 
AI
